Blackcrane Capital’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Blackcrane Capital’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-25,641	Closed	-$2.2M	–	15
2020 Q4	$2.2M	Sell	25,641 -18,471	-42%	-$1.57M	4.32%	7
2020 Q3	$2.87M	Sell	44,112 -78,753	-64%	-$5.16M	6.69%	6
2020 Q2	$8.98M	Sell	122,865 -145,003	-54%	-$7.72M	10.16%	4
2020 Q1	$9.12M	Sell	267,868 -32	-0%	-$1.46K	8.33%	6
2019 Q4	$14.6M	Buy	267,900 +172	+0.1%	+$8.52K	11.64%	2
2019 Q3	$11.2M	Buy	+267,728	New	+$11.3M	14.86%	3

Other funds holding BHVN

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

RP Management New York $139M AUM 37.98% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Blackcrane Capital's BHVN Position: Q1 2021 in Review

Blackcrane Capital sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q1 2021, closing a stake of 25,641 shares — an estimated $2.2M sold.

Blackcrane Capital first reported a position in BHVN in Q3 2019 and held it in 6 quarters. The position peaked at $14.6M in Q4 2019. 224 funds tracked by Wall St. Rank hold BHVN as of Q1 2021.

Blackcrane Capital reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q1 2021 after selling out during the quarter.
Blackcrane Capital sold 25,641 Biohaven Pharmaceutical Holding Company Ltd. shares in Q1 2021, an estimated $2.2M.
Blackcrane Capital first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q3 2019 and held it in 6 quarters.
Blackcrane Capital's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $14.6M in Q4 2019.
224 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q1 2021.

Based on Blackcrane Capital's 13F filing for Q1 2021, filed 13 May 2021.